Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/35811
Title: Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era
Authors: SIERRA, Pablo S.CORDEIRO, Mauricio D.V, Emanuel AlbuquerqueBASTOS, Diogo A.BONADIO, Renata C.SARKIS, Alvaro S.CAVALCANTE, AlexandrePONTES JR., JoseCOELHO, Rafael F.NAHAS, William C.
Citation: CLINICAL GENITOURINARY CANCER, v.18, n.2, p.E134-E144, 2020
Abstract: We studied the oncologic outcomes of young adults with kidney cancer who were treated after the introduction of targeted therapy. Additionally, we analyzed the impact of young age (< 40 years) on survival and recurrencefree survival. We found that young patients usually present with more advanced stages of the disease and have worse overall survival. Background: The objective of this study was to determine the outcomes of young adults with kidney cancer treated during the targeted therapy era and evaluate the impact of young age on survival. Materials and Methods: We reviewed the records from 445 patients younger than 55 years with kidney cancer at a single institution from 2006 to 2017. Overall survival (OS) and recurrence-free survival were estimated with the Kaplan-Meier method and log-rank test. Cox proportional hazards regression was used to determine the impact of clinical and pathologic variables on all-cause mortality. Results: Overall, 104 (23%) patients 40 years or younger were compared with 341 (77%) patients who were 41 to 55 years old. Younger patients presented with more advanced stages of the disease, including metastasis at diagnosis, positive lymph nodes, venous tumor thrombus and had more non-clear cell tumors (54% vs. 30%; P < .001). Young adults had significantly worse OS at 2 and 5 years (67% vs. 82% and 53% vs. 69%, respectively). Younger patients with metastatic disease received targeted agents less often compared with the older group (64% vs. 75%). There was no difference in recurrence-free survival across patients with localized disease. Independent prognostic factors associated with increased mortality were metastasis at diagnosis, pT2 or greater, and age younger than 40 years (hazard ratio, 1.65; 95% confidence interval, 1.0-2.6; P = .03). Conclusion: Patients younger than 40 years with kidney tumors treated during the targeted therapy era have worse OS compared with older adults. Young age is an independent predictor of mortality.
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MCG
Departamento de Cirurgia - FM/MCG

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/55
LIM/55 - Laboratório de Urologia

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar


Files in This Item:
File Description SizeFormat 
art_SIERRA_Oncologic_Outcomes_in_Young_Adults_With_Kidney_Cancer_2020.PDF
  Restricted Access
publishedVersion (English)826.81 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.